In a groundbreaking study that intersects the realms of metabolism and immunotherapy, researchers have unveiled a novel mechanism by which ketone body metabolism influences the responsiveness of hepatocellular carcinoma (HCC) to immune checkpoint blockade (ICB) therapy. Tumor immunotherapy, particularly via ICB, has revolutionized cancer treatment by reinvigorating the immune system against tumors. Yet, a significant proportion of patients with HCC exhibit resistance to such therapies, leaving clinicians and scientists eager to decode the metabolic underpinnings influencing therapeutic outcomes. This new research provides a compelling mechanistic insight into how metabolic reprogramming within cancer cells modulates their susceptibility to immunotherapy, highlighting a critical, previously unappreciated role of the enzyme OXCT1.
At the heart of this discovery is OXCT1, a key enzyme traditionally recognized for its rate-limiting role in ketone body catabolism. Interestingly, researchers found that elevated OXCT1 expression in tumor biopsies correlated with poorer outcomes following ICB therapy in HCC patients. Conversely, the metabolite β-hydroxybutyrate (BHB), which serves as the substrate for OXCT1, displayed an inverse relationship with therapy success, suggesting that the tumor’s ability to utilize ketone bodies via OXCT1 significantly impacts immune-mediated tumor eradication. This paradoxical finding challenges the conventional understanding of tumor metabolism and beckons a deeper dive into the molecular crosstalk between metabolism and immune regulation.
Delving into the cellular dynamics, the team discovered that glucose deprivation—a common metabolic stress within the tumor microenvironment—triggers a critical post-translational modification of OXCT1. Specifically, AMP-activated protein kinase (AMPK), a master regulator of energy metabolism, phosphorylates OXCT1 at serine 113. This modification serves as a molecular switch that exposes an otherwise obscured nuclear localization sequence within OXCT1, prompting its translocation from the cytoplasm into the cell nucleus. This translocation event marks a paradigm shift in the functional repertoire of OXCT1, extending its metabolic role beyond the mitochondria to chromatin regulation.
Once inside the nucleus, OXCT1 adopts a non-canonical role: it physically interacts with the transcription factor IRF1, a pivotal regulator of immune gene expression. This complex acts locally to metabolize BHB directly at the chromatin level, thereby reducing the availability of BHB for histone β-hydroxybutyrylation (Kbhb) on histone H3K9 residues. Histone modifications like H3K9 β-hydroxybutyrylation are epigenetic marks known to generally promote gene transcription. By consuming BHB near critical genomic loci, nuclear OXCT1 effectively suppresses Kbhb at the promoters of genes encoding major histocompatibility complex class I (MHC-I) molecules and chemokines, both essential for robust anti-tumor immune responses.
The repression of MHC-I and chemokine gene expression through this metabolic-epigenetic axis creates an immunosuppressive microenvironment, dampening the capacity of cytotoxic T cells to recognize and eliminate tumor cells. The significance of this finding lies in elucidating a mechanistic link whereby tumor metabolic status dynamically sculpts immune evasion strategies, illuminating how metabolic reprogramming directly alters the epigenetic landscape to favor immune escape. This insight aligns with emerging concepts that cancer metabolism and immune modulation are intricately intertwined rather than separate therapeutic realms.
Perhaps most exciting is the therapeutic potential unveiled by these findings. The researchers demonstrated that pharmacological or genetic disruption of the AMPK−OXCT1−IRF1 pathway sensitizes HCC tumor cells to immune checkpoint inhibitors, especially when combined with a ketogenic diet—a high-fat, low-carbohydrate nutritional approach that elevates circulating ketone levels like BHB. This combinatorial strategy synergizes to enhance tumor immunogenicity and overcome resistance, opening a novel avenue for personalized metabolic-immunotherapy strategies in HCC and potentially other cancers reliant on ketone metabolism.
This study not only advances scientific understanding of ketone body biology in cancer but also underscores the critical need to consider metabolic states as mutable factors within the tumor microenvironment that dictate immune surveillance and therapy outcomes. The nuclear translocation of OXCT1 unveils a previously unrecognized epigenetic regulatory mechanism controlled by metabolism, which could be exploited for biomarker development, patient stratification, and crafting next-generation immunometabolic therapies.
By bridging cellular metabolism, epigenetic modification, and immune regulation, this research embodies the growing appreciation that cancer is a systemic and adaptive disease. It challenges the one-dimensional perspective of metabolic enzymes as mere metabolic catalysts, repositioning them as multifaceted agents directly influencing gene expression programs pivotal for the tumor-immune interplay. This sophisticated level of regulation adds complexity to our understanding but also equips researchers and clinicians with new targets to manipulate the cancer immunity cycle more effectively.
Moreover, the work suggests that metabolic interventions like ketogenic diets may have untapped roles in modulating tumor immunity by influencing ketone availability and utilization. While ketogenic diets have been explored primarily for their systemic metabolic effects, this mechanistic insight justifies further clinical exploration to harness dietary modulation as an adjunct in immunotherapy regimens.
The methodological rigor behind these discoveries combines multiomics analyses—integrating transcriptomics, epigenomics, metabolomics, and proteomics—on patient tumor biopsies treated with immune checkpoint blockade. This comprehensive approach captures the dynamic metabolic-epigenetic alterations within clinically relevant contexts, strengthening the translational relevance of the findings. Such integrative methodologies represent the future of cancer research by providing holistic views of tumor biology necessary for innovative therapy designs.
This research reframes the landscape of cancer immunotherapy by implicating metabolic enzymes as gatekeepers of epigenetic states that determine immune gene accessibility. Therapeutically targeting these non-canonical functions could circumvent intrinsic and acquired immunotherapy resistance mechanisms that have long hindered patient outcomes in hepatocellular carcinoma and potentially other solid tumors.
Continued exploration into the diverse roles of metabolic enzymes in the nucleus promises to unravel additional layers of complexity linking metabolism and gene regulation. Such discoveries could yield a new class of metabolic-epigenetic checkpoints—offering novel intervention points to boost anti-tumor immunity synergistically with established immunotherapies.
In summary, this study compellingly illuminates how nuclear translocation of OXCT1 under metabolic stress conditions subverts the epigenetic regulation of immune genes to promote immune evasion in hepatocellular carcinoma. By unveiling this previously unknown mechanistic nexus between ketone metabolism, histone modification, and immune transcriptional control, the research opens promising new horizons for enhancing immunotherapy efficacy through precise metabolic reprogramming. The findings underscore the power of integrating metabolism-centric perspectives into immuno-oncology and inspire future efforts to develop targeted interventions that restore tumor immune visibility and responsiveness.
Understanding such complex immunometabolic interactions is pivotal for overcoming some of the most pressing challenges in modern oncology. As cancer therapies evolve, leveraging knowledge of the intimate cross talk between tumor metabolism and immune regulation will be essential to designing holistic treatment paradigms that achieve durable responses across diverse patient populations.
Subject of Research: The interplay between ketone body metabolism, epigenetic regulation, and immune gene transcription influencing immunotherapy responsiveness in hepatocellular carcinoma.
Article Title: Nuclear OXCT1 attenuates histone β-hydroxybutyrylation-mediated MHC-I transcription.
Article References:
Hu, Z., Lv, W., Wen, T. et al. Nuclear OXCT1 attenuates histone β-hydroxybutyrylation-mediated MHC-I transcription. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-026-02229-7
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41589-026-02229-7
Tags: cancer immunotherapy resistance factorsepigenetic regulation of immune geneshepatocellular carcinoma immune resistancehistone modification in cancerimmune checkpoint blockade therapyketone body metabolism in tumorsketone metabolism and tumor immunitymetabolic reprogramming in cancerMHC-I suppression mechanismsnuclear OXCT1 functiontumor microenvironment metabolismβ-hydroxybutyrate role in immunotherapy
